{"id":"NCT02145182","sponsor":"Alexion Pharmaceuticals, Inc.","briefTitle":"Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)","officialTitle":"A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multi-center Study of Eculizumab for the Prevention of Delayed Graft Function After Kidney Transplantation in Adult Subjects at Increased Risk of Delayed Graft Function.","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2014-08-21","primaryCompletion":"2016-11-22","completion":"2016-11-22","firstPosted":"2014-05-22","resultsPosted":"2018-12-17","lastUpdate":"2018-12-17"},"enrollment":288,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Delayed Graft Function"],"interventions":[{"type":"DRUG","name":"Eculizumab","otherNames":["Soliris"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Active","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to determine if eculizumab is safe and could be used to prevent delayed graft function (DGF) following kidney transplantation.","primaryOutcome":{"measure":"Percentage Of Participants With Delayed Graft Function (DGF) In The First Seven Days Post-transplant","timeFrame":"First 7 days post transplantation","effectByArm":[{"arm":"Eculizumab","deltaMin":35.9,"sd":null},{"arm":"Placebo","deltaMin":41.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.3983"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":22},"locations":{"siteCount":78,"countries":["United States","Australia","Brazil","Canada","Czechia","France","Germany","Italy","Spain"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":92,"n":142},"commonTop":["Anaemia","Hyperkalaemia","Oedema peripheral","Constipation","Hypertension"]}}